Skip to content
GLP-1 Scorecard
Menu

Evidence review

Compounded vs. Brand-Name GLP-1: What Actually Differs

A side-by-side on compounded and brand-name GLP-1 medications — approval status, oversight, sourcing, and how to weigh the trade-offs.

By The Scorecard Lab, Provider Testing Desk

"Compounded" and "brand-name" are not two grades of the same product. They are two different regulatory categories that happen to contain the same active molecules. Understanding the distinction is the difference between an informed choice and a guess dressed up as a bargain.

The two categories, defined A brand-name GLP-1 is a finished drug that a manufacturer took through the FDA's approval process — clinical trials, manufacturing review, and official labeling. Wegovy (semaglutide) is the approved brand for chronic weight management; its FDA prescribing information spells out the approved doses, warnings, and contraindications[[cite:1]].

A compounded GLP-1 is prepared by a pharmacy for a specific patient's need rather than mass-produced under an approved application. Compounded drugs are not FDA-approved and do not undergo the agency's premarket review for safety and effectiveness2. That is not automatically a mark against them — compounding is a long-standing, legal practice — but it is the central fact that everything else follows from.

Who makes compounded GLP-1, and under what rules Compounding happens under two sections of federal law. Section 503A covers a licensed pharmacist compounding for an individual patient in a state-licensed pharmacy; section 503B covers registered "outsourcing facilities" that compound larger batches under current good manufacturing practice (CGMP) requirements[[cite:3]]. A 503B facility is held to a manufacturing standard closer to a brand maker; a 503A pharmacy is not. When a provider offers compounded medication, ask which type of pharmacy fills it — the answer changes the oversight you are getting. We go deeper on this in [is compounded semaglutide legit and safe?](/is-compounded-semaglutide-legit-and-safe)

The trade-offs, graded **Approval and evidence.** Brand-name products carry FDA approval and the trial record that earned it. Compounded versions rely on the same active ingredient but were not individually reviewed. If regulatory approval is a hard requirement for you, the decision is already made.

**Consistency.** An approved product is manufactured to a fixed specification every time. Compounded preparations can vary by pharmacy in concentration, inactive ingredients, and formulation — which is exactly why the sourcing question in our six-point checklist matters so much.

**Price.** Compounded products are frequently marketed at a lower monthly cost, which is much of their appeal. Because pricing shifts constantly and is set by each provider, treat any figure as a quote to verify, not a fact — we break down the moving parts in what compounded GLP-1 costs per month.

**Availability.** Compounded supply and its legal footing depend on drug-shortage status and the specific pharmacy. Availability that exists today may not exist tomorrow, so read your provider's terms rather than assuming continuity.

Same molecule, different accountability It is tempting to conclude that because the active ingredient is identical, the products are interchangeable. They are not — not because the chemistry differs, but because the accountability does. With a brand-name product, the FDA reviewed the manufacturer. With a compounded product, you are trusting the pharmacy and the provider that chose it. That trust can be well placed, but it should be earned with transparent answers, not assumed.

How to decide Start with your non-negotiables. If FDA approval is one, choose brand-name and move on. If cost or access is driving the decision and you are comfortable with the compounding framework, insist on knowing the pharmacy type (503A vs. 503B), the exact formulation, and the prescriber behind it. Either path can be reasonable; only one of them can be reasonable *by default*, and it is not the compounded one. Compare graded providers on both sides in our [reviews](/research) and [comparisons](/compare).

Frequently asked questions

Is compounded GLP-1 the same as brand-name?

It contains the same active molecule but is a different regulatory category. Brand-name products are FDA-approved and reviewed for safety and effectiveness; compounded products are prepared by a pharmacy and are not FDA-approved.

What is the difference between a 503A and 503B pharmacy?

A 503A pharmacy compounds for an individual patient under state licensure; a 503B outsourcing facility compounds larger batches under FDA current good manufacturing practice (CGMP) requirements, a higher manufacturing standard.

Is compounded cheaper than brand-name?

It is often marketed at a lower monthly price, which is much of its appeal. Because pricing is set by each provider and changes frequently, always treat a quoted figure as something to verify at your maintenance dose.

References

  1. U.S. Food and Drug Administration (2021). WEGOVY (semaglutide) injection — Highlights of Prescribing Information. Drugs@FDA (Application No. 215256). https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
  2. U.S. Food and Drug Administration (2024). Compounding and the FDA: Questions and Answers. FDA.gov — Human Drug Compounding. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  3. U.S. Food and Drug Administration (2024). FD&C Act Provisions that Apply to Human Drug Compounding (Sections 503A and 503B). FDA.gov — Human Drug Compounding. https://www.fda.gov/drugs/human-drug-compounding/fdc-act-provisions-apply-human-drug-compounding

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Continue reading